{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}],"title":"Complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"title":"VGPR-Very good partial remission"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"CR :Negative immunofixation on the serum and urine and Disappearance of any soft tissue plasmacytomas and \\<=5% plasma cells in bone marrow.\n\nVGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100mg per 24 hour.\n\nPartial Response:\\>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to \\<200mg per 24 hour.","groups":[{"description":"All patients received melphalan (100 mg/m\\^2/day × 2; days\n\n-3 and -2), for a total dose of 200 mg/m\\^2. Patients were randomized to receive bortezomib 24 hours before administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg/m\\^2","id":"OG000","title":"Bortezomib Before Melphalan"},{"description":"patients received melphalan (100 mg/m\\^2/day × 2; days\n\n-3 and -2), for a total dose of 200 mg/m\\^2. Patients were randomized to receive bortezomib 24 hours after administration of high-dose melphalan in escalating dose cohorts of 1.0, 1.3, and 1.6 mg/m\\^2","id":"OG001","title":"Bortezomib After Melphalan"}],"paramType":"NUMBER","populationDescription":"As per the protocol.","reportingStatus":"POSTED","timeFrame":"100 days after transplant","title":"Response Rate Using EBMT(European Group for Blood and Bone Marrow Transplan) Criteria at Day +100 After Transplant.","type":"SECONDARY","unitOfMeasure":"participants"}